secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001193125-24-233794
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio appoints Philippe Sauvage as CFO effective October 7, 2024
-----------------------------------------------------------------------

- Philippe Sauvage appointed CFO; previously SVP Global Head of Operations & Access at Sanofi (2020-2024).
- Initial annual base salary of $510,000; annual discretionary bonus up to 45% of base.
- Option award for 750,000 shares; vests 1/4 on one-year anniversary, then monthly vesting.
- Severance: 12 months base salary plus COBRA reimbursement; change-in-control double trigger with full equity acceleration.
- No family relationships or material transactions with directors or officers disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524233794/0001193125-24-233794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524233794/d787897d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-233794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer